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Study patients. Patients referred to the Massachusetts 
General Ijospital between November 1984 and May 1988 for 
diagnostic right ventricular biopsy to exclude the diagnosis 
of active myocarditis were asked to participate in this study. 
The study protocol and consent form had been approved by 
the hospital’s Subcommittee on Human Studies. During this 
time, 289 patients underwent endomyocardial biopsy; an- 
timyosin imaging was performed in 82 of these patients. 
Patient, enrollment was based on the availability of the 
radiolabeled antimyosin antibody (which was often limited) 
and of nuclear medicine personnel. No attempt was made to 
select or exclude patients for study on the basis of their 
clinical presentation. The 82 patients were compared with a 
group of 50 randomly selected patients who underwent 
biopsy without imaging during this time and no differences 
were found in demographic data, severity or duration of 
heart failure, left ventricular ejection fraction, incidence of 
biopsy-verified myocarditis orclinical outcome. 
These 82 patients underwent right and left heart catheter- 
ization, coronary arteriography, right ventricular endomyo- 
cardial biopsy and cardiac imaging employing monoclonal 
antimyosin Fab labeled with indium-1 11 and form the basis 
of this report. Normal coronary anatomy was demonstrated 
in all patients by selective coronary ngiography. 
Seventy-four patients (Group I) had dilated cardiomyop- 
athy at the time of presentation, with a global left ventricular 
ejection fraction 50.45 by either left ventriculography or 
equilibrium-gated blood pool imaging; the remaining eight 
patients (Group II) had nondilated cardiomyopathy. Group I
comprised 50 men and 24 women with a mean age of 43 + 2 
years (range 17 to 70) and a mean left ventricular ejection 
fraction at the time of biopsy of 0.30 f 0.02. The majority of 
Group I patients (90%) presented with heart failure af cl2 
months’ duration; 8% had symptomatic ventricular tachy- 
cardia or fibrillation and one patient (2%) had chest pain a d 
ECG findings that mimicked acute myocardial infarction. 
Five patients had had aprevious episode of biopsy-verified 
myocarditis and presented with a second episode of heart 
failure that suggested reactivation f their disease. 
Group II comprised four men and four women with a left 
ventricular ejection fraction >0.45 (mean 0.59 f 0.03; range 
0.48 to 0.75). Three Group II patients presented with acute 
onset of chest pain and ECG changes mimicking acute 
myocardial infarction, one patient had chest pain, atria1 
fkiliation of recent onset and a pericardial effusion and the 
remaining four patients had unexplained right- and left-sided 
heart failure, normal left ventricular function and hemody- 
namic findings consistent with restrictive/constrictive phys- 
iology. The acute clinical presentation in each of the eight 
Patients prompted the referring physician to undertake en- 
domyocardial biopsy to exclude myocarditis. 
Figure 1. Photomicrograph of a representative ar a of a biopsy 
specimen that demonstrates myocarditis. A dense focus of mono- 
nuclear inflammatory cellsis seen adjacent to necrotic myocytes 
(hematoxylin-eosin; original magnification x320, reduced by 25%). 
~iQ~sy asd 
. Patients underwent right ventricular 
biopsy by means of the right internal jugular vein as previ- 
ously described (1,4,5). Multiple biopsy specimens (u ually 
five to seven, each measuring 2 to 3 mm in diameter) were 
obtained from the right ventricular septum using a Caves- 
Schultz-Stanford bioptome and were immediately fixed by 
immersion i buffered 10% formalin (4). Paraffin sections 
were stained with hematoxylin-eosin, Itdasson’s trichrome 
and Congo red. Specimens were divided into three catego- 
ries on the basis of light microscopic studies as previously 
described (12). Specimens defined as showing myocarditis 
contained an inflammatory infiltrate adjacent to necrotic or 
degenerating myocytes, with a variable amount of interstitial 
fibrosis (Fig. 1). Specimens showing myocyte hypertrophy, 
interstitial or replacement fibrosis, or both, but no evidence 
of myocarditis were classified as showing nonspecific 
changes. Normal specimens showed no diagnostic abnor- 
malities. All biopsy samples were analyzed without prior 
knowledge of the antimyosin scan results. 
Indium=lII monoclonal ntimyosin cardiac scintigraphy. 
Monoclonal ntimyosin Fab coupled to diethylenetriamine- 
pentaacetic a id was radiolabeled with indium-111 (Cento- 
car) (9). After informed consent was obtained, 500 ccg of 
antimyosin Fab labeled with 1.8 mCi (66.6 mBq) of indium- 
111 was administered through aperipheral vein within 48 h 
of endomyocardial biopsy. Ungated planar and single photon 
emission computed tomographic (SPECT) images were ob- 
tained at 48 h after administration f the radioactive agent as 
previously described (9). Ungated planar images were ob- 
tained in the anterior and 40 to 50” left anterior oblique views 
through a medium energy collimator with the pulse height 
analyzers set at center lines of 173 and 247 keV (20% window 
for each). For the SPECT imaging, p:ltients were positioned 
3. A RQ~af ~t~yos~n i 
bin the liver, spteen and spi no activity isevident inthe 
cardiac region GR planar or c~~~na~ s. Aate~o~ 
and left anterior blique views as in Figure 2. 
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Table 1. Comparison of Right Ventricular Biopsy Findings and 
Antimy& Imaging in 82 Patients With Suspected Myocarditis 
Antimyosin 
Right Ventricular Biopsy Results 
Scan Results Myocarditls Nondiagnostic 
Abnormal IS 30 
NOlllld 3 -1 
The probability hat either the two columns or the two rows of this table 
were drawn from the same population was 0.014 by the Fischer’s te t. 
The infiltrate was lymphocytic n12 patients and the remain- 
ing 6 patients had giant cell myocarditis. Thirteen of the 18 
patients had dilated cardiomyopathy on admission (mean left 
ventricular ejection fraction 0.25 2 0.03). Symptoms at 
presentation in this group included cardiogenic shock (n = 
2), class III or IV heart failure symptoms (n = 8) and 
ventricular tachycardia orfibrillation (n = 3). Five patients 
had a normal left ventricular ejection fraction at the time of 
initial biopsy, four had lymphocytic myocarditis and the 
remaining patient had giaut cell myocarditis. Four of the five 
Group II patients with myocarditis presented with chest pain 
and abnormal ECG findings that mimicked acute myocardial 
infarction; the remaining patient had unexplained biventric- 
ular heart failure. Right ventricular biopsy showed nonspe- 
cific changes including myocyte hypertrophy and interstitial 
or replacement fibrosis, or both, in 27 patients (33%), normal 
myocardium in 22 patients (270/o), interstitial or replacement 
fibrosis, or both, alone in 7 patients (9%), myocyte hyper- 
trophy alone in 3 patients (4%), resolved myocarditis n4 
patients (5%) and amyloidosis in 1 patient. 
Results of initial antimyosin maging. The correlation 
between histologic findings on right ventricular biopsy and 
antimyosin scintigraphic imaging is shown in Table 1. Car- 
diac imaging using indium-111 antimyosin antibody frag- 
ments was abnormal in 45 patients (55%) and normal in the 
remaining 37 (45%). Tracer uptake was heterogeneous rather 
than diffuse within the left ventricle in all 45 patients with an 
abnormal scan. The anterior wall and apex of the left 
ventricle were the most frequent sites of antimyosin uptake. 
No tracer uptake was noted within the right ventricular 
myocardium. Nonspecific intracavitary biood pool activity 
was often evident on planar images obtained at 24 h, but bad 
resolved by 48 h. Fifteen of the 18 patients with myocarditis 
on endomyocardial biopsy had an abnormal antimyosin 
scan. or’ the three patients with myocarditis and a normal 
scan, one had normal left ventricular size and functicn and 
presented with chest pain; another presented with cardio- 
genie shock and underwent imaging while on intraaortic: 
balloon support. The images obtained inthis patient were of 
poor quality and read as equivocal. 
ThirrY patients had no evidewe of myocarditis on biopsy, 
but had an abnormal antimyosin scan. All but two had 
dilated cardiomyopathy and presented with symptomatic 
heart failure. Histologic findings in this group were as 
follows: normal myocardium (n= 12); nonspecific changes, 
predominantly myocyte hypertrophy and interstitial fibrosis 
(n = 15); amyloidosis (n = 1); cardiac sarcoidosis (n = 1); 
and resolved myocarditis (n= 1). A normal antimyosia scan 
was obtained in 37 patients; myocarditis was evident on 
biopsy in 3 patients, myocyte hypertrophy or fibrosis, or 
both, in 22 patients, normal myocardium in 9 patients, and 
resolved myocarditis in3 patients who bad previously doc- 
umented active disease. By employing right ventricular 
histologic findings as the indicator for the presence or 
absence of myocarditis, the following results were obtained: 
antimyosin scan sensitivity = 83%; antimyosin scan speci- 
ficity = 53%; predictive value of an abn 
and predictive value of a normal scan = 
. Figure 4 shows the observed changes 
in left ventricular ejection fraction over time for 25 Group I
patients with an abnormal ntimyosin scan. Patients were 
classified into two groups: Group IA contained 11 patients 
with an abnormal scan and biopsy-verified myocarditis, and 
Group I6 contained 28 patients with an abnormal scan but 
nondiagnostic biopsy results. Left ventricular ejection frac- 
tion was obtained during initial evaluation a d after 6 months 
of medical therapy. Repeat assessment of left ventricular 
function was obtained in 10 of the 11 Group IA patients. 
Nine of these 10 Group IA patients received immunosup- 
pressive therapy: 7 received acombination ofazatbioprine 
and prednisone and 2 received prednisone alone, An in- 
crease in left ventricular ejection fraction 10.1 was achieved 
in 7 of these 10 patients; the mean group ejection fraction 
increased from 0.27 -t 0.02 to 0.43 -t- 0.04 (p = 0.01). 
Six*?en of the 28 Group BB patients (abnormal scalz, 
nondiagnostic biopsy results) underwent a second determi- 
nation of ventricular function. None of these patients re- 
ceived immunosuppressive therapy and seven demonstrated 
a spontaneous increase in left ventricular ejection fraction 
>O. 1. In several cases, the improvement was dramatic, with 
an increase in ejection fraction from CO.20 to >0.55 and 
complete resolution of symptoms. The mean ejection frac- 
tion in Group IB increased from 0.32 I 0.03 to 0.43 -c 0.05 
(p = 0.05). Of the 26 patients with an abnormal ntimyosin 
scan (Groups IA and IB) who underwent repeat evaluation, 
54% demonstrated improvement (7of the 10 patients with 
biopsy-verified myocarditis [Group IA]; 7 of the 16 patiems 
with a nondiagnostic biopsy [Group IB], p = NS). 
Five of the eight Group I!! patients (nondilated cardiomy- 
opathy) had biopsy-verified myocarditis. 0 2patient had 
sarcoid myocarditis and received immunosuppressive tb r- 
apy with prednisone for 6 months. The remaining four 
patients with myocarditis with normal left ventncu!ar func- 
tion did not receive immunosuppressive therapy. Aatimyo- 
sin imaging was abnormal in four of the five patients with 
myocarditis (Group HA). Two additional Group II patients 
had an abnormal ntimyosin scan; replacement fibrosis and 
myocyte hypertrophy were seen on biopsy in one patient and 
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Figure 4. Change in left ventricular ejection 
fraction over time is displayed fm each Group 
I patient (see text) with an abnormal antimy- 
osin scan. Patients are divided into 9 with 
myocarditis on right ventricular biopsy 
anel) and 16 without his- 
1013 of myocarditis Group 
AMAB = a~t~rnyQsi~ aati-
ight ventricular smdomyo- 
cardial biopsy. 
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the other had normal myoca 
had a normal scan and biopsy. Left 
fraction was reassessed in 
not change (0.66 + 0.04 to 
patients did not undergcr repeat assessmem of ventricular 
function, but were clinically improved at 6 month follow-up 
study. 
Figttxe 5, The observed change in left ventricular ejection fraction 
for 22 Group I patients with a normal antimyosin scan over time. 
Abbreviations as in Figure 4. 
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months for Group I patients with u norma/ ~~ti~yosi~ scan 
and rtondiagnostic biopsy results. Twenty-two of the 34 
patients underwent repeat study and none of these patients 
received imm~~~s~~pre5s~ve therapy. Spontaneous im- 
provement in left ventricular function was seen in four 
patients (18%). Hn 0ne patient, the increase in ejection 
fraction was dramatic (9.2? to O.70), whereas the remaining 
three. patients had less ~rn~ress~~re changes in ventricular 
functisn. The mean group ejection fraction was 0.19 * 0.E 
and mcreased only slightly to 8.24 -+ 8.03 (p = NS). A 
comparison of the observed chaitges in left ventricular 
ejection fraction between antimyosin scan-normal and scan- 
abnormal (Groups IA and 18) patients with depressed ven- 
tricular functton demonstrated a significant difierence. Clin- 
ical and hem~dynam~~ improvement occurred in 54% of 
patients with an abnormal scan within 6 months compared 
with 18% of patients with a normal scan tp < 0.01). 
Rest&s of repeat ant~my~sin imagisms Serum samples 
were obtained before injection of the second dose of antimy- 
osin and no antimurine Fab antibodies to the agent were 
detected. All patients underwent repeat study without diffi- 
culty. 
Five patients whose initial antimyosin scan was normal 
returned 6 to 12 months later for a second etermination and 
a$l five continued to lack evidence far antimyosin uptake. 
None of these patients demonstrated improvement in ven- 
tricular function during the follow-up eriod. 
Sevenreen of the $5 patients with an initial abnormal 
uiztimyosin scan irturnedjir repeat study. Repeat antimyo- 
sin imaging remained abnormal t 6 months in 9 of the 17 
patients. Seven of these nine patients had biopsy-verified 
myocarditis atthe time of initial imaging; five had ilated 
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cardiomyopathy and the remaining two patients with myo- 
cardhis had normal eft ventricular function. Immunosup 
pressive therapy was administered in four of the five patients 
with myocarditis and dilated cardiomyopathy and resulted in
histologic resolution of myocarditis. Nonetheless, they con- 
tinued to have evidence of markedly abnormal ntimyosin 
uptake. Despite the presence of ngoing antimyosin uptake, 
four of the nine patients demonstrated clinical improvement; 
three of these four patients had active myocarditis on initial 
biopsy and demonstrated a substantial ncrease in left ven- 
tricular ejection fraction after immunosuppressive therapy 
and the fourth patient had myocarditis and normal eft 
ventricular function and demonstrated spontaneous clinical 
improvement with complete resolution of symptoms. 
Eight patients whose scans were initially abnormal had a 
follow-up antimyosin scan that no longer demonstrated 
tracer uptake. Three of these eight patients had biopsy- 
verified myocarditis that had resolved on repeat endomyo- 
cardial biopsy during immunosuppressive therapy. Left ven- 
tricular function improved in two of these three Group IA 
patients. Left ventricular function also improved in four 
Group IB patients with nondiagnostic biopsy results and 
remained unchanged in the remaining patient. Overall, 43% 
(three of seven) of the Group I patients with continued 
antimyosin uptake had improvement i  ventricular function 
compared with a 75% (six of eight) improvement rate for 
patients whose repeat scan no longer demonstrated tracer 
uptake (p = NS). 
utility of anthnyoshl iac imaging in the dlagnnsis of 
active myocardiis. The differentiation f patients with left 
ventricular dysfunction due to active myocarditis from the 
much larger group of patients with idiopathic dilated cardio- 
myopathy remains difficult and currently requires endomy- 
ocardial biopsy. Myocarditis, however, isdetected inonly a 
small percent of patients with acute or chronic heart failure; 
most series yield a rate of detection of 2% to 15% (13). It 
would be highly desirable to have a noninvasive screening 
test for myocarditis with sufficient sensitivity to correctly 
identify those patients who should undergo this invasive 
procedure. This study conlirms and broadens our initial 
observations concerning the utility of antimyosin cardiac 
imaging in the diagnosis of active myocarditis (11). Antimy- 
o,sin scintigraphy records one of the two essential compo- 
nents of myocarditis (namely, m ocardial necrosis) andis 
relatively insensitive tomyocardial inflammation (7,lO). An- 
timyosin imaging was found to be 83% sensitive and 53% 
specific for the detection f myocarditis among a heteroge- 
neous group of patients with varied clinical presentations, 
including sudden cardiac death, acute and chronic conges- 
tive heart failure, chest pain mimicking myocardial infarc- 
tion and cardiogenic shock. 
Furthermore, the technique also proved usefu 
ing myocarditia in patients with 
left ventricular systolic function. 
value of a normal ntimyosin scan, was reported as 
our initial pilot study (11) of 28 patients, was still foxed to be 
highly predictive of normal biopsy results, with a predictive 
value of 92% in this larger and more heterogeneous group of 
patients. Based on a small sample size, thes 
that endocardial biopsy is 
the presence ofa normal an 
further consideration as to t 
the need for biopsy. 
ive 
variety of noninva- 
to be useful in the 
detection of experimental and clinical myocarditis. Retro- 
spective clinical studies have examined the role of gallium-67 
(14), nuclear magnetic resonance imaging (15) and cytoim- 
munologic monitoring (16). Although none have d 
strated sufficient accuracy to eliminate the n ed for 
myocardial biopsy, gallium-67 imaging (when pe~o~ed at 
centers with extensive experience in the technique) has been 
reported (14,17) useful, both as a screening tool and in 
predicting the response to immunosuppressive tb ~~y. 
O’Connell et al. (17) reported a sensitivity of 36% and a
specificity of 98% for gallium cardiac imaging in the detec- 
tion of myocarditis. Gallium imaging differs from antimyosin 
imaging because it localizes to areas of inflammation and 
thus detects the inflammatory component of myocarditis, 
whereas ant,imyosin a tibodies are specific toareas of myo- 
cyte necrosis. Both may be aseful as screening tools because 
they help identify the two bligate components of myocardi- 
tis. Although the observed predictive value of 33% for an 
abnormal ntimyosin scan was lower than anticipated, an 
abnormal scan was still useful as a screening tool; the yield 
of right ventricular biopsy during the 4 years of this study in 
patients who did not undergo antimyosin maging averaged 
only 13%. 
IWe negative ~~rny~i~ scans. Although an infrequent 
occurrence, a normal antimyosin scan occurred in three 
patients (17%) with biopsy-verified myocarditis. Suboptimal 
cardiac imaging in one critically ill patient accounted for one 
of the false negative scans. It is possible that his technique 
could have failed todetect myocarditis that was character- 
ized by an active inflammatory infiltrate but little myocyte 
necrosis. Conversely, myocyte necrosis may have been 
present but the number of foci too small to result in detection 
of tracer activity above that of normal background, espe- 
cially if primarily confined to the right ventricle. 
Positive scan and biopsy discordauce. Of
are the 30 patients who had no evidence of 
biopsy but unequivocal mtimyosin uptake. Three patients 
had a probable cause for antimyosin uptake: two had infil- 
trative disease (cardiac amyloidosis and sarcoidosis) and the 
blood pool activity from t 
ventricular function was independent of koading conditions 
because medical therapy remained unaltei’ed or had de- 
creased in a!! improved patients witir ventricular ~nnction. 
A!thougb these findings uggest that a subgrou 
with an abnormal ntimyosin scan may have, 
e right ventricular biopsy failed ts detect, 
no definite conclusion can be drawn. We are cu ntly 
evaluating the ro!e of repeat left ventricuiar biopsy the 
area of myocardia! uptake in this group of patients with an 
abnormal scan. 
~~t~rnyosi take a m&s. The presence of an- 
timyosin uptake on initial cardiac imaging served as a 
prognostic ndication of subsequent improvement in ventric- 
ular function. A clinicdly relevant. @crease inleft ventricular 
ejection fraction occurred in 54% of patients with an abnor- 
mal scan compared with only 18% of patients with a normal 
scan. These findings are also in keeping with those of 
O’Connell et al. (171, who reported improvement i  ventric- 
ular function during immunosuppressive th rapy in 40% of 
patients whose initial gallium scan was abnorma! compared 
with 30% of those with a normal ga!!ium scan in patients not 
receiving immunosuppressive th rapy. Similar data have 
a!so recently been reported by Parillo et a!. (20). Given the 
likelihood of spontaneous improve ent in ventricular func- 
tion and the known risks of corticosteroids, the ro-. *:f 
immunosuppressive th rapy for the treatment of patrel.L 
with nondiagnostic biopsy results and an abnormal ntimy- 
osin scan will require aprospective clinical tria!. The relation 
between ongoing myocardial inflammation and continued 
but potentially reversible depression ofventricular function 
currently remains unresolved. 
@ur data 2 
evidence fix i 
the cotrcept that t 
aGon as ~~~g~~ by 
either s~~n~an~~~~§~~ or 
. Tbe presence of contln- 
~~stol~gi~ activity of 
s in v~n~r~cn!ar- func- 
though four of five pzfients with biopsy-verified myocarditis 
and normal !eft ventricular function were correctly identi- 
fied, the utility of ant~myosin imaging in detecting myocardi- 
tis in this group of patients remains to be more completely 
defined. Further, clinical fo !ow-up data were not availabie 
for a!! patients who nnde~ent initial antimyosi 
Overall, 65% of patients underwent a second etermination 
of ventricular function within 6 months of initial study. 
Clinical follow-up data were avai!ab!e in 66% of~at~ents with 
an abnormal scan and 62% oft a normal scan; 6% 
of patients died before repeat &ion of ventricular 
function. Whether ciinica! fo!! in the remaining 
patients would have led to a better assessment of t 
prognostic significance of the initial antimyosin results 
uncertain. 
Finally, it would have been useful to have performed a 
greater number of repeat antimyosin scans. A!thongb it is 
encouraging that repeat studies were normal in all patients 
whose initial scan lacked antimyosin uptake, the small 
sample size of patients with an abnormal scan precluded any 
accurate valuation of t&e significance of either cortinued 
antimyosin uptake or conversion from 
scan-normal status. It was evident that s 
tion of antimyosin uptake can occur and tbat resolution of 
myocardia! necrosis as judged by endomyocardial biopsy 
was not a!wayq associated with resolution of antimyosin 
uptake. The explanation for observed ifferences between 
scan and biopsy findings wi!! require aParger study group and 
possibly serial scans and biopsies. 
Couchtsion. This study confirms the usefmness Of an, 
timyosin scmtigraphy as a screening method in the initial 
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evaluation of patients with heart failure due to clinically 
suspected myocardit~s and further defines its role in the 
selection of patients for endomyocardial biopsy. The ab- 
sence of cardiac antimyosin uptake was highly predictive 
(92%) of a biopsy that did not detect my~~ditis and may 
obviate the need for biopsy in most patients with normal 
scans who have unexplained heart failure. Patients with 
abnormal ~tim~~sin scans houfd undergo biopsy in order 
to histologically verify the diagnosis of myocarditis when- 
ever immu~suppres~iv~ therapy is being contemplated. 
Whether antimpsin imaging can be used to guide further 
diagnostic procedures such as left ventricular biopsy in the 
presence ofprominent left ventricular Ntimyosin uptake or 
to predict a response to planned treatment is currently 
undergoing investigation. 
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